Managing Severe Hemophilia A in Children: Pharmacotherapeutic Options

References

• Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–1939. doi:10.1111/jth.12672
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544. doi:10.1056/NEJMoa067659
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lundin B, Von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT study). J Thromb Haemost. 2011;9(4):700–710. doi:10.1111/j.1538-7836.2011.04214.x
   PubMed Web of Science ®Google Scholar
• Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia. 2003;9(3):272–278. doi:10.1046/j.1365-2516.2003.00757.x
   PubMed Web of Science ®Google Scholar
• Warren BB, Thornhill D, Stein J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the joint outcome continuation study. Blood Adv. 2020;4(11):2451–2459. doi:10.1182/bloodadvances.2019001311
   PubMed Web of Science ®Google Scholar
• Gouw SC, Van Den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046–4055. doi:10.1182/blood-2012-09-457036
   PubMed Web of Science ®Google Scholar
• Ragni MV, Ojeifo O, Feng J, et al. Risk factors for inhibitor formation in haemophilia: a prevalent case-control study. Haemophilia. 2009;15(5):1074–1082. doi:10.1111/j.1365-2516.2009.02058.x
   PubMed Web of Science ®Google Scholar
• Van Den Berg HM, Fischer K, Carcao M, et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood. 2019;134(3):317–320. doi:10.1182/blood.2019000658
   PubMed Web of Science ®Google Scholar
• Gouw SC, Van Der Bom JG, Van Den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4648–4654. doi:10.1182/blood-2006-11-056291
   PubMed Web of Science ®Google Scholar
• den Uijl IEM, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia. 2011;17(6):849–853. doi:10.1111/j.1365-2516.2011.02539.x
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia. 2008;14(SUPPL. 3):10–18. doi:10.1111/j.1365-2516.2008.01708.x
   PubMed Web of Science ®Google Scholar
• Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion. 1999;39(December):1160–1168. doi:10.1046/j.1537-2995.1999.39111160.x
   PubMed Web of Science ®Google Scholar
• Björkman S, Blanchette VS, FischeR K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8(4):730–736. doi:10.1111/j.1538-7836.2010.03757.x
   PubMed Web of Science ®Google Scholar
• Morfini M, Marchesini E, Paladino E, Santoro C, Zanon E, Iorio A. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study. Haemophilia. 2015;21(2):204–209. doi:10.1111/hae.12550
   PubMed Web of Science ®Google Scholar
• Versloot O, Iserman E, Chelle P, et al. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database. J Thromb Haemost. 2021;19(8):1896–1906. doi:10.1111/jth.15395
   PubMed Web of Science ®Google Scholar
• Turecek PL, Johnsen JM, Pipe SW, O’Donnell JS. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia. Haemophilia. 2020;26(4):575–583. doi:10.1111/hae.14078
   PubMed Web of Science ®Google Scholar
• Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia. 2010;16(SUPPL. 5):181–188. doi:10.1111/j.1365-2516.2010.02318.x
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Peters R, Harris T. Advances and innovations in haemophilia treatment. Nat Rev Drug Discov. 2018;17(7):493–508. doi:10.1038/nrd.2018.70
   PubMed Web of Science ®Google Scholar
• Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016;128(16):2007–2016. doi:10.1182/blood-2016-04-713289
   PubMed Web of Science ®Google Scholar
• Ragni MV. New and emerging agents for the treatment of hemophilia: focus on extended half-life recombinant clotting proteins. Drugs. 2015;75(14):1587–1600. doi:10.1007/s40265-015-0451-5
   PubMed Web of Science ®Google Scholar
• Ragni MV, Croteau SE, Morfini M, Cnossen MH, Iorio A. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(7):1437–1441. doi:10.1111/jth.14153
   PubMed Web of Science ®Google Scholar
• Chhabra ES, Liu T, Kulman J, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood. 2020;135(17):1484–1496. doi:10.1182/BLOOD.2019001292
   PubMed Web of Science ®Google Scholar
• Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as Factor VIII replacement therapy for Hemophilia A. N Engl J Med. 2020;383(11):1018–1027. doi:10.1056/nejmoa2002699
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. Online registry of clotting factor concentrates. World Federation of Hemophilia website; 2018.
   Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–818. doi:10.1056/NEJMoa1703068
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors; 2018.
   Google Scholar
• Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130(23):2463–2468. doi:10.1182/blood-2017-08-801662
   PubMed Web of Science ®Google Scholar
• Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127–2138. doi:10.1182/blood.2019001869
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med. 2018;379(9):811–822. doi:10.1056/NEJMoa1803550
   PubMed Web of Science ®Google Scholar
• Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295–e305. doi:10.1016/S2352-3026(19)30054-7
   PubMed Web of Science ®Google Scholar
• Jimenez-Yuste V, Peyvandi F, Klamroth R, et al. Final analysis of the STASEY trial: a single-arm, multicenter, open-label, Phase III clinical trial evaluation the safety and tolerability of emicizumab prophylaxis in persons with Hemophilia A (PwHA) with Factor (F) VIII Inhibitors. Res Pr Thromb Haemost. 2021;5(Suppl1):17–21.
   PubMedGoogle Scholar
• Lucas TL, Gupta S, Davis JA, Corrales-Medina FF. Emicizumab-Kxwh for previously untreated patients with haemophilia: the conversation begins. Blood. 2019;134(Supplement_1):2409. doi:10.1182/blood-2019-127270
   Web of Science ®Google Scholar
• ATHN 7: hemophilia natural history study; 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03619863. Accessed September 21, 2021.
   Google Scholar
• Bolliger D, Szlam F, Suzuki N, Matsushita T, Tanaka KA. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice. Thromb Haemost. 2010;103(6):1233–1238. doi:10.1160/TH09-10-0732
   PubMed Web of Science ®Google Scholar
• Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21(5):492–497. doi:10.1038/nm.3847
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Lissitchkov T, Mamonov V, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19(6):1436–1446. doi:10.1111/jth.15270
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Georgiev P, Mant T, et al. Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: updated results from a Phase 1 and Phase 1/2 extension study in patients with inhibitors. Blood. 2016;128(22):1397. doi:10.1182/blood.v128.22.1397.1397
   Web of Science ®Google Scholar
• Alnylam suspends fitusiran dosing due to thrombotic event in Phase 2 open-label extension study. World Federation of Hemophilia; 2017. Available from: https://news.wfh.org/alnylam-suspends-fitusiran-dosing-due-thrombotic-event-phase-2-open-label-extension-study/. Accessed December 30, 2021.
   Google Scholar
• Update: FDA lifts suspension of fitusiran trial. World Federation of Hemophilia; 2017. Available from: https://news.wfh.org/update-fda-lifts-suspension-fitusiran-trial/. Accessed December 30, 2021.
   Google Scholar
• Taylor NP. Sanofi plans 2021 restart for pediatric hemophilia trial hit by fallout from thrombotic events. Fierce Biotech; 2021. Available from: https://www.fiercebiotech.com/biotech/sanofi-plans-2021-restart-for-pediatric-hemophilia-trial-hit-by-fallout-from-thrombotic. Accessed December 30, 2021.
   Google Scholar
• Kato H. Tissue factor pathway inhibitor; its structure, function and clinical significance. Pol J Pharmacol. 1996;48(1):67–72.
   PubMedGoogle Scholar
• Eichler H, Angchaisuksiri P, Kavakli K, et al. Concizumab restores thrombin generation potential in patients with haemophilia: pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data. Haemophilia. 2019;25(1):60–66. doi:10.1111/hae.13627
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019;134(22):1973–1982. doi:10.1182/blood.2019001542
   PubMed Web of Science ®Google Scholar
• Ray F. Novo nordisk resumes Phase 3 trials of concizumab in Hemophilia A and B. Hemophilia News Today; 2020.
   Google Scholar
• Mahlangu J, Lamas J, Morales J, et al. A Phase 1b/2 study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of PF-06741086, an anti-TFPI monoclonal antibody, in patients with Severe Hemophilia A or B. Res Pr Thromb Haemost. 2019;3:85–86.
   PubMed Web of Science ®Google Scholar
• Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy, marstacimab, for people with severe hemophilia A and B with or without inhibitors. Dow Jones Institutional News. Available from: https://cmich.idm.oclc.org/login?url=https://www.proquest.com/wire-feeds/press-release-pfizer-doses-first-participant/docview/2463381584/se-2?accountid=10181. Accessed December 30, 2021. 2020.
   Google Scholar
• Kjellev SL, Østergaard H, Greisen PJ, et al. Mim8 - A next-generation FVIII mimetic bi-specific antibody - potently restores the hemostatic capacity in hemophilia a settings in vitro and in vivo. Blood. 2019;134(Supplement_1):96. doi:10.1182/blood-2019-122817
   Web of Science ®Google Scholar
• Østergaard H, Lund J, Greisen P, et al. FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138:1258–1268. doi:10.1182/blood.2020010331
   PubMed Web of Science ®Google Scholar
• McIntosh J, Lenting PJ, Rosales C, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. 2013;121(17):3335–3344. doi:10.1182/blood-2012-10-462200
   PubMed Web of Science ®Google Scholar
• Nathwani AC. Gene therapy for hemophilia. Hematol Am Soc Hematol Educ Progr. 2019;1:1–8. doi:10.1002/pbc.26865
   Web of Science ®Google Scholar
• Gollomp KL, Doshi BS, Arruda VR. Gene therapy for hemophilia: progress to date and challenges moving forward. Transfus Apher Sci. 2019;58(5):602–612. doi:10.1016/j.transci.2019.08.012
   PubMed Web of Science ®Google Scholar
• Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A. https://clinicaltrials.gov/ct2/show/NCT04418414.
   Google Scholar
• Gene therapy trial for platelet derived factor VIII production in Hemophilia A. 2021. Available from: https://www.fiercebiotech.com/biotech/sanofi-plans-2021-restart-for-pediatric-hemophilia-trial-hit-by-fallout-from-thrombotic. Accessed December 30, 2021.
   Google Scholar
• Carmona G, Barney L, Sewell J, et al. Correcting rare blood disorders using coagulation factors produced in vivo by shielded living therapeutics products. Blood. 2019;134(Supplement 1):2065. doi:10.1182/blood-2019-127050
   Web of Science ®Google Scholar
• Shapiro A, Konkle B, Croteau S, et al. First-in-human Phase 1/2 clinical trial of SIG-001, an innovative shielded cell therapy platform, for hemophilia A. Blood. 2020;136(Supplement 1):8. doi:10.1182/blood.2020006611
   PubMed Web of Science ®Google Scholar
• Al Idrus A. FDA puts Sigilon’s hemophilia cell therapy trial on hold thanks to safety concerns. Fierce Biotech; 2021.
   Google Scholar
• Leavitt A, Konkle B, Stine K, et al. Updated follow-up of the alta study, a Phase 1/2 study of giroctocogene fitelparvovec (SB-525) gene therapy in adults with severe Hemophilia A. Blood. 2020;136(Supplement1):12. doi:10.1182/blood-2020-137648
   Web of Science ®Google Scholar
• Study to evaluate the efficacy and safety of PF-07055480/giroctocogene fitelparvovec gene therapy in moderately severe to severe Hemophilia A adults. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT04370054&cntry=&state=&city=&dist=. Accessed September 21, 2021.
   Google Scholar
• Long BR, Veron P, Kuranda K, et al. Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for Hemophilia A. Mol Ther. 2021;29(2):597–610. doi:10.1016/j.ymthe.2020.12.008
   PubMed Web of Science ®Google Scholar
• Study to Evaluate the Efficacy and Safety of Valoctogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (GENEr8-3). https://clinicaltrials.gov/ct2/show/NCT04323098.
   Google Scholar
• George LA, Monahan PE, Eyster ME, et al. Phase I/II Trial of SPK-8011: stable and durable FVIII expression after AAV gene transfer for Hemophilia A. Res Pr Thromb Haemost. 2021;5(Suppl 1):17–21.
   PubMedGoogle Scholar